AKT1 and head and neck squamous cell carcinoma: However, as demonstrated particularly by the Gutkind laboratory, molecular targeting of mTOR seems a promising approach in HNSCC broadly, as 80–90% of all HNSCCs show activation of the PI3K/Akt/mTOR axis [19].